Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...

AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...

Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

A study presented at CROI 2025 reveals that a single-question self-efficacy measure effectively predicts ART adherence and viral load suppression among pregnant women with HIV in Malawi, offering a ...

A 15-year study by Kaiser Permanente Northern California reveals significant gaps in LTBI testing practices, highlighting the need for targeted strategies to prevent active TB cases.

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...